A literature review about cardiovascular risk in patients with kidney disease
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20231416Keywords:
Kidney, Cardiovascular risk, Risk factorsAbstract
More than 700 million individuals are thought to have chronic kidney disease (CKD) globally, and the incidence is continuing to rise as a result of an aging population and the spread of chronic illnesses like diabetes and hypertension. The most common cause of morbidity and death in nephropathy patients is cardiovascular disease. In clinical practice, managing nephropathy and cardiovascular risk in nephropathic patients is a significant problem. Each patient needs a thorough examination and specialized treatment. To lower the risk of cardiovascular events in nephropathy patients, cardiovascular risk factors must be prevented and promptly treated. To increase the quality of life and survival of nephropathic patients, it is crucial to recognize and treat cardiovascular problems.
References
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7-11.
Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney and Dialysis. 2022;2(3):433-42.
Dattani R, McAdoo S. Secondary glomerular disease. Medicine. 2019;47(10):644-8.
Hiyamuta H, Yamada S, Taniguchi M, Nakano T, Tsuruya K, Kitazono T. Causes of death in patients undergoing maintenance hemodialysis in Japan: 10-year outcomes of the Q-Cohort Study. Clin Exp Nephrol. 2021;25(10):1121-30.
Hussain S, Jamali MC, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clin Epidemiol Global Health. 2021;9:2-6.
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-72.
Kattah A. Preeclampsia and kidney disease: deciphering cause and effect. Current Hypertens Rep. 2020;22:1-11.
Negre-Salvayre A, Guerby P, Gayral S, Laffargue M, Salvayre R. Role of reactive oxygen species in atherosclerosis: Lessons from murine genetic models. Free Radic Biol Med. 2020;149:8-22.
Bravo-Zúñiga J, Gálvez-Inga J, Carrillo-Onofre P, Chávez-Gómez R, Castro-Monteverde P. Early detection of chronic renal disease: coordinated work between primary and specialized care in an ambulatory renal network of Peru. J Bras Nefrol. 2019;41(2):176-84.
Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, Pagidipati NJ. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. J Am Coll Cardiol. 2022;79(18):1849-57.
Aleidan FAS, Ahmad BA, Alotaibi FA, Aleesa DH, Alhefdhi NA, Badri M, et al. Prevalence and Risk Factors for Diabetic Peripheral Neuropathy Among Saudi Hospitalized Diabetic Patients: A Nested Case-Control Study. Int J Gen Med. 2020;13:881-9.
Colantonio LD, Hubbard D, Monda KL, Mues KE, Huang L, Dai Y, et al. Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2020;76(3):251-64.
Hussain S, Jamali MC, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clin Epidemiol Global Health. 2021;9:2-6.
Sagoo MK, Gnudi L. Diabetic Nephropathy: An Overview. Methods Mol Biol. 2020;2067:3-7.
Chrysant SG. The debate over the optimal blood pressure treatment target of less than 130/80 mmHg. Postgrad Med. 2023;135(3):208-13.
Thobani A, Jacobson TA. Dyslipidemia in patients with kidney disease. Cardiol Clin. 2021;39(3):353-63.
Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: beyond erythropoietin. Adv Therap. 2021;38(1):52-75.
Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies. 2019;5:3-15.
Roehm B, Gulati G, Weiner DE. Heart failure management in dialysis patients: many treatment options with no clear evidence. In Seminars in dialysis. 2020;33(3):198-208.
